Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 262.55M P/E - EPS this Y -14.30% Ern Qtrly Grth -
Income -27.63M Forward P/E -5.41 EPS next Y -2.10% 50D Avg Chg -7.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 2.00%
Dividend N/A Price/Book 2.65 EPS next 5Y - 52W High Chg -66.00%
Recommedations 1.50 Quick Ratio 11.00 Shares Outstanding 69.92M 52W Low Chg 38.00%
Insider Own 25.63% ROA -21.92% Shares Float 52M Beta 0.78
Inst Own 2.03% ROE -33.17% Shares Shorted/Prior 40.85K/20.20K Price 3.79
Gross Margin - Profit Margin - Avg. Volume 55,037 Target Price 9.25
Oper. Margin - Earnings Date - Volume 14,894 Change -2.32%
About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd. News
11/19/24 Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/24 Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference
11/01/24 Discover Alpha Tau Medical And 2 Other US Penny Stocks
10/21/24 Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
10/11/24 Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment
10/10/24 Alpha Tau Treats First Patient with Recurrent Lung Cancer
09/23/24 FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment
09/20/24 Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
09/17/24 Sidoti Events, LLC's Virtual September Small-Cap Conference
09/03/24 DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT
08/22/24 Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
08/14/24 Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
06/25/24 Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
05/21/24 Alpha Tau to Present at the Jefferies Global Healthcare Conference
05/20/24 Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
05/13/24 Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
05/06/24 Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
05/01/24 Alpha Tau to Participate in May Investor Conferences
03/25/24 Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
03/07/24 Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
DRTS Chatroom

User Image Thestocktraderhubzee Posted - 2 days ago

WATCHLIST NOV 22 2024 $DRTS HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target $PCOR Piper Sandler Maintains Overweight on Procore Technologies, Raises Price Target to $90 $ZIM Jefferies Maintains Hold on ZIM Integrated Shipping, Raises Price Target to $28 $UTI Truist Securities Maintains Buy on Universal Technical, Raises Price Target to $26 $GNTX Guggenheim Maintains Buy on Gentex, Lowers Price Target to $34

User Image Freddie___Mac Posted - 3 days ago

$CATX $DRTS

User Image Freddie___Mac Posted - 3 days ago

$CATX look at $DRTS for local alpha radiation treatment that works. Different approach, but a much higher efficacy and potential

User Image Freddie___Mac Posted - 4 days ago

$DRTS several catalysts in 1q 2025...

User Image Witspro Posted - 5 days ago

$DRTS someone knows something

User Image pawbar Posted - 1 week ago

$DRTS I wonder how likely is the approval by PMDA in Japan.... it's not a process that can be easily monitored by investors...

User Image Dirtymartini66 Posted - 1 week ago

$DRTS come on man - wtf? still long but this is ridiculous - this can't catch a bid - something is seriously wrong here - time for me to put a fork in it - sorry guys/gals - but this is f'd up

User Image Zaneyone Posted - 1 week ago

$XBI The biotech bulls are back. Breakout Alert on XBI. Buy, buy, buy! Next up $PSTV, $DRTS, $SLS & RIGL that just went bonkers too. Why will XBI continue to climb? Well lots of big pharma patents are about to/have expired and big pharma is actively hunting for new growth catalysts to acquire/partner with (first step) with MB$ pipelines they can capitalize on. If you liked my RIGL & SMMT picks for massive gains, you will love your return on investment in PSTV. One year chart and new investors brief attached below. Currently, PSTV is a low float Strong Buy at perfect buy in point on chart with 4 Buy ratings from Analysts. PSTV's ER & investor CC will be Nov. 14th. ****BUY THE FEAR AND YOU WILL FLY IN A LEAR (JET). ****

User Image Zaneyone Posted - 2 weeks ago

$PSTV $XBI $SLS $DRTS

User Image Zaneyone Posted - 10/31/24

$XBI $PTSV $SLS $DRTS The biotech sector is full of novel cancer treatments that are working well against the deadliest cancers. Each of these small cap biotech Co. will likely be 10 x gainers if their cancer treatments continue to fulfill their promises in clinical trials. PSTV will be submitting a new medical device application for Rhenium-188 NanoLiposomes (188RNL-BAM) with the FDA soon probably in Q4. These microspheres will be delivered into vital organs like the liver, kidneys etc. kill cancer (virtually no damage to surrounding tissues), and the radioactivity fades away shortly after (Rhenium 188 has a 2 week half life). These microspheres are a revolutionary breakthrough in cancer treatment for Austin TX based Plus Therapeutics. PSTV has established that Rhenium 186 works effectively, safely, and efficiently to kill cancer with the FDA in clinical trials 1/2. So, investors will see the FDA approval in mere months. https://plustherapeutics.com/188RNL-BAM/ Buy in while these stock are dirt cheap!

User Image pawbar Posted - 10/30/24

$DRTS a potential Japanese approval could move this to $4 or higher? Not sure what's the addressable market in Japan, but it could be at least the first approval. Not sure on the future sales structure etc. But it could be a good catalyst (or maybe not.. you never know how the market reacts...)

User Image Gu4 Posted - 1 month ago

$DRTS every time

User Image MakingDreamsReality Posted - 1 month ago

PM mOOvers 👀 $KVUE - Kenvue shares are trading higher following a report suggesting Starboard Value has acquired a stake in the company. $KIRK -Kirkland shares are trading higher after the company announced that Beyond will invest $25 million. $VSEE -VSee Health Expands its Telehealth Service Offering with New GLP-1 Program to Address Obesity and Chronic Disease $LUMN -Lumen and Meta Partner to Drive AI Network Expansion $DRTS -Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

User Image Zaneyone Posted - 1 month ago

$XBI $PSTV $DRTS $SLS Innovative cancer treatments are red hot M&A candidates right now, as demonstrated by Novartis' 3 acquisitions in 2024. Read full details here... https://www.fiercebiotech.com/biotech/novartis-pays-baiyu-70m-upfront-11b-chaser-small-molecule-cancer-candidate Crazy undervalued PSTV has multiple catalysts. PSTV has had excellent clinical results, has an impressive pipeline, more MM$ grant revenue in the works, has acquired CNS testing for new source of lasting MM$ revenue, will submit new medical device application to FDA soon for Rhenium 188 nanospheres for liver cancer (Med. devices can be approved in six months) for future MM$ in revenue. I'm not sure which treatment will be approved first Rhenium 186 for glioblastoma or Rhenium 188 nanospheres for liver cancer but it does not matter with robust clinical results, high safety, lives being saved from deadly cancers. PSTV's MB$ M&A possibilities ahead, low float, recent insider buying, and the BULLISH inverse head & shoulders chart pattern (profitable 89% of time) all point up. Average PT is $14.67/sh. per TipRanks.

User Image Gu4 Posted - 1 month ago

$DRTS

User Image Dirtymartini66 Posted - 1 month ago

$DRTS any idea why we're dipping again?

User Image Freddie___Mac Posted - 1 month ago

$DRTS https://www.linkedin.com/posts/alphataumedical_catch-prof-yigal-shoshan-head-of-neurosurgery-activity-7249382242760740864-2-Kw Talking GBM trial tomorrow. Hebrew speakers please keep us posted :)

User Image Gu4 Posted - 1 month ago

$DRTS

User Image Dirtymartini66 Posted - 2 months ago

$DRTS fun little reminder - Avg Analyst Price target $9.25 - High $13, low $7. All time high ($20) end of March '22, smacked down to $5 May '22 - then hovered between $10 - $13 ~ Jun thru Sep '22 - before dropping off to $5 and deteriorating to where we are now. But now - it has a much rosier picture - positive clinical trial data - Japan approval months away - and analyst's estimates look very bullish, even on the low end and as a kicker in a very sought after market niche by big pharma https://finance.yahoo.com/quote/DRTS/analysis/

User Image Freddie___Mac Posted - 2 months ago

$DRTS no idea who's selling but hope they get out finally. Liquidity is bad but it can move a LOT higher really fast

User Image Stocks4thought Posted - 2 months ago

$DRTS should do a major move- Israel stocks - muck with you- when they work- they make fortunes. Stay with it$

User Image Gu4 Posted - 2 months ago

$DRTS Very strange🤨

User Image _www_larval_com_ Posted - 2 months ago

$DRTS just reverted -7% lower to 1% (~80Kv) a moment ago, 09/20 options, follow for more volatility.

User Image Stock_Titan Posted - 2 months ago

$DRTS $DRTSW Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC https://www.stocktitan.net/news/DRTS/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-fgc2exxlrqut.html

User Image back2unodder Posted - 2 months ago

$DRTS --So Inv Hub had interesting article link --https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html

User Image Freddie___Mac Posted - 2 months ago

$CATX yall missing out a hidden gem $DRTS in the local treatment of solid tumors using alpha radiation...

User Image pawbar Posted - 2 months ago

$DRTS any word when we can expect Japan approval?

User Image pawbar Posted - 2 months ago

$DRTS The treatments od DRTS seem to work, but aren't they too invasive for a wide adoption in clinical practice? It appears less invasive treatments may become reality in the meantime.

User Image DomeniaSalvia Posted - 08/31/24

$DRTS This stock is involved in sectors related to technology and digital solutions. Its performance is driven by its innovations and market strategies.

User Image Dirtymartini66 Posted - 3 months ago

$DRTS wow - no volume - total shares traded today - per ST = 49

Analyst Ratings
HC Wainwright & Co. Buy Aug 20, 24
Piper Sandler Overweight Aug 15, 24
HC Wainwright & Co. Buy Jun 26, 24
HC Wainwright & Co. Buy May 22, 24
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy Mar 12, 24
Piper Sandler Overweight Mar 8, 24
Citigroup Buy Dec 15, 23
HC Wainwright & Co. Buy Nov 20, 23